FDA accepts priority review for Kite Pharma ’s refractory aggressive NHL treatment

The US Food and Drug Administration (FDA) has accepted priority review for cell therapy company Kite Pharma ’s biologics licence application (BLA) for axicabtagene ciloleucel to treat patients with refractory aggressive non-Hodgkin lymphoma (NHL).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news